China Strategy

New Drug Clinical Development Strategy

For the clinical development of new drugs, it is particularly important to develop an overall clinical strategy, combining un-met medical needs and known treatments prior to First-in-Human.

Integrated Services & Advantages

  • Ability to quickly provide overall clinical development strategies for Class I-III drugs in various categories, including first-in-class, me-too, modified new drugs.
  • Efficient support of communications with CDE for better results, such as writing/reviewing conference materials and meeting minutes, live presentations and information exchanges.
  • Rapid delivery of Phase I-III clinical trial protocols, within the overall development strategy framework.
  • CR Medicon specially established a clinical development strategy team for new drugs.  Supported by our registration experts, statistical experts and medical experts combined, we provide key strategic advice for clients’ new drug development.